AlphAIAlphAI — Financial news for AI agents
theglobeandmail.comOCT 121 min read$EVMN

Evommune, Inc. (EVMN) Receives a Hold from UBS

UBS initiated coverage on Evommune, Inc. with a Hold rating and a $8.00 price target. The analyst consensus is Strong Buy with an average target of $22.40. The company reported a Q2 GAAP net loss of $32.25M, up from $13.57M last year.

Original reporting
theglobeandmail.com
Published Oct 12, 2026, 11:07 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 5:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Evommune, Inc. (EVMN) Receives a Hold from UBS — source image
Source · theglobeandmail.com
Decision brief

The 30-second read

$EVMNBearishMed
01

Why it matters

Analyst downgrade and lower price target suggest downside pressure.

02

Market read

likely pressure as the market prices in the reduced target and Hold rating

03

Timing

today

Relevance 6/10Novelty 6/10Timing: today
Company-level read

Ticker impact

$EVMNBearishHigh confidence
Context

UBS initiated coverage with a Hold rating and set a price target of $8, while the consensus remains a Strong Buy at $22.40, alongside a reported quarterly GAAP net loss of $32.25 million.

Expected impact

likely pressure as the market prices in the reduced target and Hold rating

Evidence & confidence

The new Hold rating and $8 target represent a significant cut from the $22.40 consensus, indicating a bearish outlook.

Read at source← All news

Related articles

OCT 20
$EVMNMed

Evommune stock initiated at Overweight by Morgan Stanley on dermatitis drug potential

Morgan Stanley initiated coverage on Evommune Inc (NYSE:EVMN) with an Overweight rating and a $26.00 price target, citing potential in its EVO301 drug for atopic dermatitis. The company's stock is down 74% over the past year, trading at $5.27. Analysts have mixed reactions following recent trial results, with some maintaining positive outlooks despite setbacks. The atopic dermatitis market is expected to grow to $26 billion by 2030, according to Morgan Stanley.

investing.com2 min
OCT 1
$EVMNHighAI 9/10

Evommune, Inc.: Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress

Evommune (NYSE: EVMN) presented Phase 2a trial data for EVO301 in atopic dermatitis at EADV 2026, showing a 55% reduction in EASI score vs. 22% for placebo. The trial met its primary endpoint, with favorable safety and tolerability. Evommune plans to start a Phase 2b trial in mid-2027.

finanznachrichten.de2 min
OCT 1
$EVMNHighAI 9/10

Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology…

Evommune, Inc. (EVMN) filed an SEC Form 8-K — Regulation FD Disclosure. Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress - Presentation highlights EVO301’s clear therapeutic signal, favorable safety and tolerability profile, and reinforces

SEC EDGAR 8-K3 min